BNP Paribas Financial Markets
ELDN icon

BNP Paribas Financial Markets’s Eledon Pharmaceuticals ELDN Stock Holding History

BNP Paribas Financial Markets’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.1K Sell
11,193
-4,860
-30% -$17.7K ﹤0.01% 4940
2026
Q1 		$49.4K Buy
16,053
+4,170
+35% +$9.82K ﹤0.01% 4698
2025
Q4 		$17.9K Sell
11,883
-271
-2% -$644 ﹤0.01% 5050
2025
Q3 		$31.5K Buy
12,154
+7,166
+144% +$20.9K ﹤0.01% 4784
2025
Q2 		$13.5K Buy
+4,988
New +$15K ﹤0.01% 4760
2017
Q1 		– Sell
-2
Closed -$370 – 4129
2016
Q4 		$370 Sell
2
-2
-50% -$383 ﹤0.01% 4074
2016
Q3 		$1.04K Buy
4
+2
+100% +$732 ﹤0.01% 3475
2016
Q2 		$2.19K Buy
+2
New +$2.21K ﹤0.01% 3443
2016
Q1 		– Sell
-16
Closed -$22.3K – 2789
2015
Q4 		$22.3K Buy
16
+3
+23% +$5.23K ﹤0.01% 3252
2015
Q3 		$22.1K Buy
13
+8
+160% +$16.5K ﹤0.01% 3277
2015
Q2 		$10.5K Buy
5
+4
+400% +$7.74K ﹤0.01% 3326
2015
Q1 		$1.62K Buy
+1
New +$2.21K ﹤0.01% 3506

Other funds holding ELDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets's ELDN Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Eledon Pharmaceuticals (ELDN) stake by 30% in Q2 2026, selling an estimated $17.7K and leaving 11,193 shares worth $44.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4940.

BNP Paribas Financial Markets first reported a position in ELDN in Q1 2015 and has held it in 12 quarters since. The position peaked at $49.4K in Q1 2026. 146 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • BNP Paribas Financial Markets held 11,193 shares of Eledon Pharmaceuticals worth $44.1K as of Q2 2026.
  • BNP Paribas Financial Markets sold 4,860 Eledon Pharmaceuticals shares in Q2 2026, an estimated $17.7K.
  • Eledon Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4940 holding.
  • BNP Paribas Financial Markets first reported a position in Eledon Pharmaceuticals in Q1 2015 and has held it in 12 quarters since.
  • BNP Paribas Financial Markets's Eledon Pharmaceuticals position peaked at $49.4K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.